What Is Methylene Blue? Structure, Research and FDA Status

Methylene blue is a synthetic blue dye, not a peptide, and FDA approved it as ProvayBlue in 2016 to treat acquired methemoglobinemia.

Basics10 min read

Key takeaway

Methylene blue is a small phenothiazinium dye with no amino acids. In the body it shuttles electrons, which is how it turns methemoglobin back into normal hemoglobin. It also strongly inhibits monoamine oxidase A, the basis of its serotonin syndrome warning. Human trials in Alzheimer's disease, septic shock and malaria have produced mixed or early results.

At a glance

Article typeBasics
TopicPeptide science
Studies cited8
Related productsResearch peptide catalog

What is methylene blue is a fair question, because one compound has been a laboratory stain, a hospital medicine and a research tool. It was first made in 1876. Today its US label carries a boxed warning about serotonin syndrome, a risk that matters when it is discussed alongside research compounds.

Quick answer: Methylene blue is a prescription medicine in the United States, sold as ProvayBlue and as approved generics. Its only US label indication is acquired methemoglobinemia in children and adults. It is a dye, not a peptide. Its label warns that combining it with serotonergic drugs or opioids may cause serious or fatal serotonin syndrome.

Vitrapep does not sell methylene blue; this page is a reference summary of published research and regulatory information.

Is methylene blue a peptide?

No. A peptide is a chain of amino acids joined by peptide bonds, as Vitrapep's guide to what peptides are explains. Methylene blue contains no amino acids. It is built on a phenothiazine core, a three-ring structure holding one sulfur and one nitrogen atom.

PubChem lists its formula as C16H18ClN3S and its molecular weight as 319.9 g/mol (PubChem). The ProvayBlue label calls it a water-soluble thiazine dye and an oxidation-reduction agent. European regulators use the name methylthioninium chloride.

Table 1

Is methylene blue a peptide

FeatureMethylene blueSource
Is it a peptide?No; a small-molecule dye with no amino acidsPubChem
Chemical classThiazine (phenothiazinium) dye; oxidation-reduction agentProvayBlue label
Molecular formulaC16H18ClN3SPubChem
Molecular weight319.9 g/molPubChem
First synthesized1876, by Caro at the chemical company BASFKrafts et al., 2011
US brand and first approvalProvayBlue, April 8, 2016 (NDA 204630, Provepharm)Drugs@FDA
US genericsSeven approved, the first on December 5, 2023Drugs@FDA
US label indicationAcquired methemoglobinemia in pediatric and adult patientsProvayBlue label
Boxed warningSerotonin syndrome with serotonergic drugs and opioidsProvayBlue label
EU authorizationsMethylthioninium chloride Proveblue (2011); Lumeblue (2020)EMA

Where did methylene blue come from?

Caro synthesized methylene blue in 1876 at BASF (Krafts et al., 2011). Six years later, Robert Koch used it when he discovered the tuberculosis bacterium. Methylene blue later became the basis of the Malachowski-Wright-Giemsa blood stain, still regarded as the standard diagnostic technique for malaria.

In 1891, Guttmann and Ehrlich reported curing two malaria patients with methylene blue. A 1995 review calls this the first report of antimalarial activity from a synthetic rather than a natural material (Vennerstrom et al., 1995).

For decades, methylene blue was used in the United States without FDA approval. FDA's 2016 review called it "a marketed unapproved drug that has been used for many decades" for acquired methemoglobinemia (FDA, 2016). FDA approved ProvayBlue, from the French company Provepharm, on April 8, 2016 (Drugs@FDA).

How does methylene blue work in the body?

Methylene blue works mainly by moving electrons. The ProvayBlue label describes two steps. First, an NADPH reductase converts it to a colorless form, leucomethylene blue. Leucomethylene blue then reduces the ferric iron of methemoglobin to the ferrous iron of normal hemoglobin.

Methemoglobin does not release oxygen to tissues as easily as normal hemoglobin. FDA's 2016 review says the acquired form follows exposure to oxidizing drugs, chemicals and toxins. Levels above 70% may be fatal.

People with glucose-6-phosphate dehydrogenase (G6PD) deficiency may not convert methylene blue to its active form, the label says. They also face a risk of severe hemolysis, the destruction of red blood cells. The label therefore lists G6PD deficiency as a contraindication.

A second action involves brain chemistry. In a 2007 study of purified human enzymes, methylene blue tightly inhibited monoamine oxidase A, or MAO-A (Ramsay et al., 2007). MAO-A breaks down serotonin. The authors concluded this would explain serotonin toxicity in patients taking SSRI antidepressants.

A third line of work concerns mitochondria, the compartments that make most of a cell's energy. In a 2008 cell study, enzymes using NAD(P)H reduced methylene blue, and cytochrome c reoxidized it (Atamna et al., 2008). Cytochrome c is part of the mitochondrial electron transport chain.

The label adds that its half-life is about 24 hours. About 40% leaves in the urine unchanged, and the dye can interfere with urine tests that use a blue indicator.

What is methylene blue approved for?

In the United States, ProvayBlue is indicated for pediatric and adult patients with acquired methemoglobinemia. Drugs@FDA also lists seven generic methylene blue applications approved between December 2023 and December 2025.

The current label rests on 31 adults in two studies: a single-arm, open-label study (NCT03395223) and an observational registry (NCT03542760). Of 28 adults with a baseline measurement, 26 had at least a 50% fall in methemoglobin at their first follow-up test. Pediatric use rests on two retrospective case series of 14 patients.

FDA's 2011 safety communication listed other hospital uses, including vasoplegic syndrome, cyanide poisoning and diagnostic dye procedures (FDA, 2011). None of these is an indication on the current US label.

In Europe, Methylthioninium chloride Proveblue was authorized on May 6, 2011, for methemoglobinemia caused by medicines and chemicals (EMA). Lumeblue followed on August 19, 2020, as a diagnostic agent that improves visualization of colorectal lesions during colonoscopy (EMA).

What have human studies of methylene blue found?

Outside methemoglobinemia, randomized human trials are few and point in different directions. Table 2 lists five of them. Only the two Alzheimer's trials enrolled more than 100 people.

Table 2

What have human studies of methylene blue found

StudyDesignPopulation and sizeDurationMain finding
Gauthier et al., 2016Randomized, double-blind Phase 3; LMTM vs a blinding control891 people with mild to moderate Alzheimer's disease15 monthsNo benefit on either co-primary outcome
Wischik et al., 2026Randomized Phase 3 with a delayed start; HMTM vs methylthioninium chloride control598 amyloid-positive people with mild cognitive impairment or mild to moderate Alzheimer's dementia104 weeksNo significant difference on co-primary outcomes at 52 weeks
Ibarra-Estrada et al., 2023Single-center, randomized, placebo-controlled91 adults with septic shock28 daysVasopressors stopped sooner (median 69 vs 94 hours); mortality similar
Rodriguez et al., 2016Randomized, double-blind, placebo-controlled brain imaging study26 healthy adults aged 22 to 62One sessionHigher fMRI responses during attention and memory tasks; 7% more correct memory answers
Dicko et al., 2018Single-blind, randomized Phase 280 G6PD-normal males aged 5 to 50 carrying malaria parasites in MaliInfectivity tested on days 2 and 7Adding methylene blue to an antimalarial cut mosquito infectivity by a median 100% on day 2

The Alzheimer's work traces back to a 1996 cell-free study, in which methylene blue blocked tau-to-tau binding (Wischik et al., 1996). Both Phase 3 trials tested TRx0237 from TauRx Therapeutics, a reduced form of the molecule. The 2016 paper called it LMTM and the 2026 paper called it HMTM.

Because these compounds discolor urine, each trial gave its control group a small amount of a methylthioninium compound to protect blinding. The 2026 authors reported symptomatic activity in that control arm, which they said prevented separation on primary outcomes. They reported differences in the mild cognitive impairment group at 78 and 104 weeks. TauRx sponsored both trials.

The septic shock trial ran at one hospital in Mexico and was registered retrospectively (NCT04446871). Its authors reported no serious adverse effects related to methylene blue and called for larger trials. The imaging study measured brain responses after a single exposure, not clinical outcomes.

What do animal and cell studies show?

In the 2008 cell study, methylene blue extended the life span of cultured human fibroblasts by more than 20 population doublings (Atamna et al., 2008). It raised mitochondrial complex IV activity by 30% and oxygen consumption by 37% to 70%. These cell results do not show effects on aging in people.

In animals, the 2016 trial paper notes that LMTM inhibited tau aggregation in transgenic mouse models. The label reports animal safety findings too. In two-year studies, methylene blue caused pancreatic islet tumors in male rats but not in mice. It was genotoxic in bacterial and hamster cell tests, and it caused embryo and fetal toxicity in pregnant rats and rabbits.

What side effects and warnings does the label list?

The label's safety data come from 31 adults with acquired methemoglobinemia. Serious adverse reactions occurred in 3.2%, a seizure-like event in one patient. Reactions in at least 2% were headache, low potassium, diarrhea, low magnesium, myoclonus (muscle jerks), nausea and seizure-like phenomena.

FDA's 2016 review also summarized a healthy-volunteer trial. Its most common events included limb pain, colored urine, taste changes, feeling hot, dizziness, sweating and skin discoloration. Table 3 lists the label's main warnings.

Table 3

What side effects and warnings does the label list

Label sectionWhat the label says
Boxed warningSerious or fatal serotonin syndrome with serotonergic drugs and opioids
ContraindicationsSevere hypersensitivity to thiazine dyes; G6PD deficiency
HypersensitivityAnaphylaxis has been reported with methylene blue class products
Hemolytic anemiaHemolysis can occur, and anemia may appear a day or more later
Monitoring devicesPulse oximeters may underestimate oxygen saturation
PregnancyMay cause fetal harm
Skin and body fluidsBlue discoloration; phototoxicity

Suspected reactions can be reported to FDA MedWatch at 1-800-FDA-1088.

Why does methylene blue carry a serotonin syndrome warning?

In July 2011, FDA reported serious central nervous system reactions in patients taking serotonergic psychiatric drugs who were given methylene blue. The reports included confusion, delirium, agitation, coma, muscle jerks, seizures and fever. FDA noted that health professionals and patients may not realize methylene blue has monoamine oxidase inhibitor properties.

An October 2011 update said most cases occurred during parathyroid surgery, where methylene blue was used as a visualizing agent. The implicated drugs were SSRIs, SNRIs and clomipramine. The current boxed warning extends to opioids. The label's interaction section also names bupropion, buspirone, mirtazapine, linezolid and dextromethorphan.

Why is methylene blue discussed alongside peptides?

The overlap is biology, not chemistry. Methylene blue relies on NADPH, a close relative of NAD+, and cell studies tie it to the electron transport chain. That places it beside compounds in Vitrapep's mitochondrial peptides overview, the NAD+ complete guide and the MOTS-c complete guide.

The differences matter more. As a non-peptide, methylene blue is not on Vitrapep's list of FDA-approved peptide medicines. It is an approved drug with a detailed label, a boxed warning and a long interaction list. Many research peptides have far less human safety data, as research peptides and human-use risks describes.

A research-use label on any product does not make it an approved medicine or legal for people. A 26-person imaging study cannot establish clinical benefit; how to evaluate peptide research explains why. Registered studies can be searched as described in how to find a peptide clinical trial.

Frequently asked questions

Is methylene blue a peptide?

No. It is a small-molecule thiazine dye with a molecular weight of 319.9 g/mol and no amino acids.

Is methylene blue FDA-approved?

Yes. FDA approved ProvayBlue on April 8, 2016, for acquired methemoglobinemia. Seven generic versions have been approved since December 2023.

Why does methylene blue have a serotonin syndrome warning?

It strongly inhibits monoamine oxidase A, an enzyme that breaks down serotonin. FDA received reports of serious reactions in patients taking serotonergic antidepressants.

Why can methylene blue turn urine and skin blue?

It is a blue dye. The label says about 40% leaves the body unchanged in urine, and it can discolor skin and body fluids.

Has methylene blue been tested in Alzheimer's disease?

Yes, as TRx0237, a reduced form. Phase 3 trials of 891 and 598 people did not meet their co-primary outcomes, and no approval has followed in the United States.

What does the label list as contraindications?

Severe hypersensitivity to methylene blue or other thiazine dyes, and G6PD deficiency, because of the risk of hemolytic anemia.

What to know now

  • Methylene blue is a synthetic thiazine dye first made in 1876; it is not a peptide.
  • FDA approved it as ProvayBlue in 2016 for acquired methemoglobinemia, its only US label indication.
  • Its boxed warning covers serious or fatal serotonin syndrome with serotonergic drugs and opioids.
  • Alzheimer's trials of a reduced form missed their primary outcomes; septic shock and malaria trials were small.

What we’re watching

  • A randomized septic shock trial at Zhejiang University (NCT06481410) planning 488 participants, with completion estimated for December 2027.
  • EMPRESS, a planned 566-patient trial in China testing whether methylene blue lowers septic shock mortality (Luo et al., 2026).
  • The UK regulator's decision on HMTM; in October 2025, TauRx said the agency required further information.
  • Further ProvayBlue label updates as generic versions enter the US market.

Also in the library

Sources: American Regent 2025; U.S. Food and Drug Administration 2016; U.S. Food and Drug Administration 2026; National Center for Biotechnology Information 2026; U.S. Food and Drug Administration 2011; European Medicines Agency 2018; Krafts 2011, Parasitology Research, 109; Vennerstrom 1995, Antimicrobial Agents and Chemotherapy, 39; Ramsay 2007, British Journal of Pharmacology, 152; Atamna 2008, FASEB Journal, 22; Gauthier 2016, Lancet, 388; Wischik 2026, Journal of Prevention of Alzheimer's Disease, 13; Ibarra-Estrada 2023, Critical Care, 27; Rodriguez 2016, Radiology, 281. All 14 citations

Back to the research library

References

  1. American Regent, Inc., & Provepharm SAS. (2025). PROVAYBLUE (methylene blue) prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f6848e5-35ed-4046-b13c-3032b5ba3232
  2. U.S. Food and Drug Administration. (2016). Summary review: NDA 204630, ProvayBlue (methylene blue). Center for Drug Evaluation and Research. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/204630Orig1s000SumR.pdf
  3. U.S. Food and Drug Administration. (2026). Drugs@FDA: NDA 204630, ProvayBlue (methylene blue). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204630
  4. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 6099, methylene blue. https://pubchem.ncbi.nlm.nih.gov/compound/6099
  5. U.S. Food and Drug Administration. (2011, July 26). FDA Drug Safety Communication: Serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications (archived copy). https://web.archive.org/web/20260309095432/www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-serious-cns-reactions-possible-when-methylene-blue-given-patients
  6. European Medicines Agency. (2018). Methylthioninium chloride Proveblue: European public assessment report. https://www.ema.europa.eu/en/medicines/human/EPAR/methylthioninium-chloride-proveblue
  7. Krafts, K., Hempelmann, E., & Oleksyn, B. J. (2011). In search of the malarial parasite: Biographical sketches of the blood stain contributors. Parasitology Research, 109(3), 521-529. https://pubmed.ncbi.nlm.nih.gov/21660627/
  8. Vennerstrom, J. L., Makler, M. T., Angerhofer, C. K., & Williams, J. A. (1995). Antimalarial dyes revisited: Xanthenes, azines, oxazines, and thiazines. Antimicrobial Agents and Chemotherapy, 39(12), 2671-2677. https://pubmed.ncbi.nlm.nih.gov/8593000/
  9. Ramsay, R. R., Dunford, C., & Gillman, P. K. (2007). Methylene blue and serotonin toxicity: Inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. British Journal of Pharmacology, 152(6), 946-951. https://pubmed.ncbi.nlm.nih.gov/17721552/
  10. Atamna, H., Nguyen, A., Schultz, C., Boyle, K., Newberry, J., Kato, H., & Ames, B. N. (2008). Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB Journal, 22(3), 703-712. https://pubmed.ncbi.nlm.nih.gov/17928358/
  11. Gauthier, S., Feldman, H. H., Schneider, L. S., Wilcock, G. K., Frisoni, G. B., Hardlund, J. H., et al. (2016). Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: A randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet, 388(10062), 2873-2884. https://pubmed.ncbi.nlm.nih.gov/27863809/
  12. Wischik, C. M., Stefanacci, R., Bentham, P., Gauthier, S., Zetterberg, H., Wilcock, G. K., et al. (2026). Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease. Journal of Prevention of Alzheimer's Disease, 13(3), 100480. https://pubmed.ncbi.nlm.nih.gov/41570392/
  13. Ibarra-Estrada, M., Kattan, E., Aguilera-González, P., Sandoval-Plascencia, L., Rico-Jauregui, U., Gómez-Partida, C. A., et al. (2023). Early adjunctive methylene blue in patients with septic shock: A randomized controlled trial. Critical Care, 27(1), 110. https://pubmed.ncbi.nlm.nih.gov/36915146/
  14. Rodriguez, P., Zhou, W., Barrett, D. W., Altmeyer, W., Gutierrez, J. E., Li, J., et al. (2016). Multimodal randomized functional MR imaging of the effects of methylene blue in the human brain. Radiology, 281(2), 516-526. https://pubmed.ncbi.nlm.nih.gov/27351678/